
Sign up to save your podcasts
Or


Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By The Wall Street Journal4.2
652652 ratings
Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices

2,851 Listeners

1,713 Listeners

4,420 Listeners

406 Listeners

427 Listeners

1,649 Listeners

1,448 Listeners

1,044 Listeners

1,320 Listeners

6,097 Listeners

1,573 Listeners

212 Listeners

1,322 Listeners

586 Listeners

151 Listeners

87 Listeners

80 Listeners

150 Listeners